Eiger BioPharmaceuticals Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Eiger BioPharmaceuticals (EIGR) Reports Q2 Loss of $1.87/Share
August 10, 2016 5:27 PM EDTEiger BioPharmaceuticals (NASDAQ: EIGR) reported Q2 EPS of ($1.87), versus ($13.34) reported last year.
For earnings history and earnings-related data on Eiger BioPharmaceuticals (EIGR) click here.
... More